BLCO: Bausch & Lomb Corp insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
98 institutions reported holding $592.24M of Bausch & Lomb Corp on Form 13F (96 the quarter before). 19 opened a new position and 15 sold out. Shares held by institutions: -2%.
| Largest holders | Shares | Value |
|---|---|---|
| ICAHN CARL C | 3,500,000 | $57.96M |
| OAKTREE CAPITAL MANAGEMENT LP | 3,441,042 | $56.98M |
| DEUTSCHE BANK AG\ | 3,423,046 | $56.69M |
| D. E. Shaw & Co., Inc. | 3,323,021 | $55.03M |
| Davidson Kempner Capital Management LP | 3,158,972 | $52.31M |
| GOLDENTREE ASSET MANAGEMENT LP | 2,660,508 | $43.96M |
| CASPIAN CAPITAL LP | 1,999,043 | $33.10M |
| GLENVIEW CAPITAL MANAGEMENT, LLC | 1,918,148 | $31.76M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,364,980 | $22.60M |
| CITADEL ADVISORS LLC | 987,730 | $16.36M |
Clinical trial readouts
2 Phase 2 or 3 trials by Bausch & Lomb Corp with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10-04 | Topical Ocular BL1332 low dose | Pain, Postoperative | Phase 2 | 130 | Completed | NCT07412496 |
| 2027-02 (est.) | BL1107 | Dry Eye Disease | Phase 2 | 20 | Not yet recruiting | NCT07778888 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.